Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

por Home, P. D.
Publicado 2015

Techniques for Ensuring That Your Next Paper Is Quite Unsuitable for Publication

por Home, P. D.
Publicado 1988

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

por Home, P. D., Lagarenne, P.
Publicado 2009

Insufficient evaluation of adverse events is not a proof of safety. Reply to LG Hemkens, U Grouven, R Bender, et al. [letter]

por Home, P. D., Lagarenne, P.
Publicado 2010

A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes

por Freemantle, N, Balkau, B, Home, P D
Publicado 2013

Biosimilar insulins: guidance for data interpretation by clinicians and users

por Heinemann, L., Home, P. D., Hompesch, M.
Publicado 2015

Relationship of glycaemic control and hypoglycaemic episodes to 4‐year cardiovascular outcomes in people with type 2 diabetes starting insulin

por Freemantle, N., Danchin, N., Calvi‐Gries, F., Vincent, M., Home, P. D.
Publicado 2015

A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes...

por Home, P D, Bailey, C J, Donaldson, J, Chen, H, Stewart, M W
Publicado 2007

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type...

por Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., Schernthaner, G.
Publicado 2008

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study

por Gordon, J, Pockett, R D, Tetlow, A P, McEwan, P, Home, P D
Publicado 2010

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardio...

por Home, P. D., Kahn, S. E., Jones, N. P., Noronha, D., Beck-Nielsen, H., Viberti, G.
Publicado 2010

Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK

por Hall, G C, McMahon, A D, Dain, M-P, Wang, E, Home, P D
Publicado 2013

Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes

por Freemantle, N, Balkau, B, Danchin, N, Wang, E, Marre, M, Vespasiani, G, Kawamori, R, Home, P D
Publicado 2012

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)...

por Bolli, G B, Riddle, M C, Bergenstal, R M, Ziemen, M, Sestakauskas, K, Goyeau, H, Home, P D
Publicado 2015

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insu...

por Riddle, M C, Yki-Järvinen, H, Bolli, G B, Ziemen, M, Muehlen-Bartmer, I, Cissokho, S, Home, P D
Publicado 2015

Rosiglitazone RECORD study: glucose control outcomes at 18 months

por Home, P D, Jones, N P, Pocock, S J, Beck-Nielsen, H, Gomis, R, Hanefeld, M, Komajda, M, Curtis, P
Publicado 2007

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes

por Home, P D, Meneghini, L, Wendisch, U, Ratner, R E, Johansen, T, Christensen, T E, Jendle, J, Roberts, A P, Birkeland, K I
Publicado 2012

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabe...

por Home, P D, Bolli, G B, Mathieu, C, Deerochanawong, C, Landgraf, W, Candelas, C, Pilorget, V, Dain, M-P, Riddle, M C
Publicado 2015